Baixar PDF

Outros usuários também visualizaram estes artigos

Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression Lucia Vráblová; Hana Klamová; Ivana Skoumalová; Jana Navrátilová; Romana Janská; Jan Grohmann; Milena Holzerová; Edgar Faber;
Hematol Transfus Cell Ther. 2024;46 Supl 6:S171-81
Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells Lena Avinery; Danielle Regev; Hazem Khamaisi; Jacob Gopas; Jamal Mahajna;
10.1016/j.htct.2025.106240
REVERSAL OF ACCELERATED PHASE CML WITH HIGH BLAST COUNT FOLLOWING 5+2 CHEMOTHERAPY AND DASATINIB: A CASE REPORT Bü¿ra Akdo¿an; Ali Turunç; Birol Güvenç;
Hematol Transfus Cell Ther. 2025;47 Supl 2: